Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II MT-3724 Monotherapy Study in Relapsed and Refractory in Diffuse-Large-B-Cell-Lymphoma Patients

Trial Profile

A Phase II MT-3724 Monotherapy Study in Relapsed and Refractory in Diffuse-Large-B-Cell-Lymphoma Patients

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs MT 3724 (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Molecular Templates
  • Most Recent Events

    • 13 Nov 2018 According to a Molecular Templates media release, the company expects to start this phase II monotherapy study in 1Q19.Also, this study has the potential to be a pivotal study.
    • 09 Aug 2018 According to a Molecular Templates media release, this monotherapy study is expected to start at the end of 2018.
    • 05 Jan 2018 According to a Molecular Templates media release, this trial is expected to begin in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top